Pentixapharm Holding AG Logo

Pentixapharm Holding AG

Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.

PTP | F

Overview

Corporate Details

ISIN(s):
DE000A383RV0 (+1 more)
LEI:
3912005VBOVXNDXEQZ36
Country:
Germany
Address:
Robert-Rössle-Straße, 10, 13125 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical development company that creates innovative, first-in-class compounds for both diagnostic and therapeutic applications. The company's pipeline primarily targets unmet medical needs in oncology, including hemato-oncology and solid tumors, as well as adrenal disorders. Key assets include two Phase III-ready drug candidates and a well-researched CXCR4-targeting compound. With a strong research and development focus, Pentixapharm has administered its compounds to over 2,000 patients in clinical settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 11:00
Regulatory News Service
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New …
English 10.5 KB
2025-09-26 08:00
Regulatory News Service
Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acut…
English 11.3 KB
2025-09-16 15:19
Director's Dealing
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.1 KB
2025-09-15 11:49
Director's Dealing
Pentixapharm Holding AG: Dr. Andreas Eckert, buy
English 5.8 KB
2025-08-06 00:00
Interim Report
Half-yearly financial report 2025
English 723.4 KB
2025-07-24 14:04
Report Publication Announcement
English 3.9 KB
2025-05-27 09:43
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
English 10.0 KB
2025-05-08 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 479.2 KB
2025-04-26 16:00
Report Publication Announcement
English 3.8 KB
2025-04-25 00:00
Annual Report
Annual financial report 2024
English 2.3 MB
2025-04-24 14:00
Regulatory News Service
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based Pentix…
English 8.8 KB
2025-04-17 15:05
Pre-Annual General Meeting Information
Pentixapharm Holding AG: Bekanntmachung der Einberufung zur Hauptversammlung am…
German 88.5 KB
2025-04-15 08:17
Report Publication Announcement
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guida…
English 6.4 KB
2025-03-19 13:20
Report Publication Announcement
English 3.9 KB
2025-03-18 13:20
Report Publication Announcement
English 3.9 KB

Automate Your Workflow. Get a real-time feed of all Pentixapharm Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pentixapharm Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.